UBX1325's selective elimination of senescent cells represents a novel approach for the treatment of diabetic retinopathy and macular edema Preclinical data featured in poster presentations at the ARVO 2021 Annual Meeting SOUTH SAN FRANCISCO, Calif., May 01, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced preclinical data demonstrating that UBX1325, a novel senolytic small molecule inhibitor of Bcl-xL, improves retinal vasculature and is differentiated from anti-VEGF agents in preclinical models. Researchers show that inhibition of retinal Bcl-xL by UBX1325 selectively promotes apoptosis of diseased senescent cells of the retina, thereby restoring healthy vasculature and improving retinal function – important distinctions from anti-VEGF treatments.